.jpg "Celldex (NASDAQ: CLDX)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Celldex (NASDAQ: CLDX) and Voyager Therapeutics Inc (NASDAQ: VYGR).
Celldex (NASDAQ: CLDX)
Cowen & Co. analyst Boris Peaker maintained a Hold rating on Celldex (NASDAQ: CLDX) today. The company’s shares opened today at $0.72, close to its 52-week low of $0.65.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.3% and a 51.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Celldex has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.
See today’s analyst top recommended stocks >>
Voyager Therapeutics Inc (NASDAQ: VYGR)
Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR) today and set a price target of $35. The company’s shares opened today at $16.76.
Kulkarni said:
“We spoke with the company who clarified that it remains comfortable on what it has said about dosing for VY-AADC. We believe eventual dosing for the pivotal Phase 2/3 trial could come in between the doses used in the initial Phase 1b, i.e., between 1.5×10 12 to 4.5×10 12 vg in 900µl/putamen. Separately, VYGR has submitted a 510(k) device application in Mar-18 for its own Guide (V-TAG) that could serve as an alternative to the ClearPoint magnetic resonance imaging (MRI) compatible device used in the procedures so far; 10-K expected a V- TAG filing in 1H18. As such, we view this pullback as a particularly good opportunity to BUY this volatile stock.”
According to TipRanks.com, Kulkarni is a 1-star analyst with an average return of -1.6% and a 41.2% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Intra-Cellular Therapies, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $36.14, representing an 115.6% upside.
In a report released today, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
